DOI: 10.1158/2643-3230.bcd-24-0236 ISSN: 2643-3230
Total (Immuno)Therapy: Version 2.0
Susan Bal, Luciano J. CostaSummary:
Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric antigen receptor T-cell therapy is now feasible.
See related article by Fandrei, p. XX